FDA Formalizes A Flavor-Specific PMTA Framework As Youth Vaping Continues To Decline
The guidance addresses the type of scientific evidence FDA expects applicants to submit
On March 9, 2026, the U.S. Food and Drug Administration (FDA) issued a new draft guidance for industry, Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk, clarifying how the agency evaluates whether a non-tobacco-flavored electronic nicotine delivery system (ENDS) product is appropriate for the protection of the public health (APPH) under section 910 of the Family Smoking Prevention and Tobacco Control Act. In particular, the draft guidance addresses the type and quantum of scientific evidence FDA expects applicants to submit to offset youth-risk concerns associated with different ENDS flavor categories.
Despite acknowledging that flavored ENDS may provide public health benefits for adult smokers, FDA makes clear that its underlying framework for premarket tobacco product application (PMTA) review remains the same. Since adopting its comparative-efficacy / fatal flaw review approach in 2021 and following the Supreme Court’s decision in FDA vs. Wages, the agency has taken the position that applications for flavored ENDS products must show an added benefit over tobacco-flavored ENDS—specifically, that the flavored product is comparatively more effective in helping adult smokers switch from combustible cigarettes or substantially reduce daily cigarette consumption. That requirement reflects FDA’s general presumption that all flavored ENDS pose greater risks to youth than tobacco-flavored products. The new draft guidance does not alter that premise; instead, it seeks to clarify how much adult-benefit evidence is necessary, with FDA stating that the amount of adult-benefit evidence needed should vary depending on the flavor category’s relative youth appeal.
FDA thus embraces a graduated, risk-proportionate approach. Put simply, flavor categories the agency believes have the greatest appeal to youth (e.g., fruit and candy/dessert/other sweet flavors) will carry the heaviest evidentiary burden. By contrast, flavors for which there may be reliable scientific evidence of relatively lower youth appeal, such as menthol, mint, and perhaps certain mature flavors like spice, tea, coffee, etc., may satisfy the APPH standard and comparative efficacy requirement with a more modest incremental showing of adult benefit.
On the youth-risk side, the draft guidance relies heavily on the proposition that flavored ENDS have been a principal driver of youth initiation and sustained use. FDA points to the National Youth Tobacco Survey (NYTS) data and other literature to support the view that young people who vape overwhelmingly use flavored products, that fruit is the leading flavor category, and that non-tobacco flavors are associated with higher odds of continued use.
To Read The Rest Of This Article On National Law Review, Click Here
